{
  "documentMetadata": {
    "title": "Mouth, Parapharyngeal Space Infection",
    "sourceFile": "Mouth, Parapharyngeal Space Infection.pdf",
    "lastUpdated": "2023-08-07"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Infections in the mouth and adjacent spaces. Consequence of septic focus in the teeth, tonsils, parotid gland, middle ear, or sinuses."
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "There are a variety of parapharyngeal spaces that can become infected:"
        },
        {
          "type": "list",
          "items": [
            "Sublingual, submandibular (Ludwig's angina if bilateral), lateral pharyngeal, retropharyngeal, pretracheal",
            "Most severe is necrotizing mediastinitis (Infection 2016;44:77; Otolaryngol Head Neck Surg 2016; 155:155)"
          ]
        }
      ]
    },
    {
      "type": "list",
      "items": [
        "Can result from poor dental hygiene, dental extractions, foreign bodies (e.g., toothpicks, fish bones).",
        "Close observation of airway indicated, 1/3 require intubation."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Diagnosis"
    },
    {
      "type": "list",
      "items": [
        "MRI or CT to identify abscess; if present, surgical drainage is indicated",
        "FDG PET CT even better at detection and extent of the infection. Medicine 2020;99:e21353"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Polymicrobic and represent the normal flora of the adjacent mucosal surfaces from which the infection originated",
        "On average 5-6 organisms cultured with anaerobic bacteria outnumbering aerobes by a ratio of 10:1.",
        "Polymicrobic:",
        "S. aureus, especially in children",
        "Streptococcus sp., especially viridans streptococci (including S. anginosis group)",
        "Anaerobes (predominant):",
        "Peptostreptococci (now Peptoniphilus sp.)",
        "Fusobacterium sp.",
        "Prevotella sp.",
        "Actinomyces sp.",
        "Others encountered less frequently: MRSA, aerobic gram-negative bacilli including P. aeruginosa. Latter in high risk groups: illicit drug use, diabetes mellitus, neutropenia, post-trauma."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Empiric Therapy"
        },
        {
          "type": "list",
          "items": [
            "Emergent surgical drainage to include aerobic and anaerobic cultures. Empiric therapy does not address possible infection with S. aureus or P. aeruginosa: see Directed/Specific Therapy"
          ]
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Ceftriaxone",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q24 h",
                "connector": "+"
              },
              {
                "drug": "Metronidazole",
                "dose": "500 mg",
                "route": "IV",
                "frequency": "q8h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Levofloxacin",
                "dose": "750 mg",
                "route": "IV",
                "frequency": "q24h",
                "connector": "+"
              },
              {
                "drug": "Clindamycin",
                "dose": "600 mg",
                "route": "IV",
                "frequency": "q8h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Ampicillin-sulbactam",
                "dose": "3 gm",
                "route": "IV",
                "frequency": "q6h"
              }
            ],
            "notes": "(Note: Increasing incidence of resistant E.coli)"
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Directed/Specific Therapy"
        },
        {
          "type": "list",
          "items": [
            "Surgical drainage cultures positive and/or immunocompromised patient and /or high risk co-morbidity"
          ]
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "condition": "Positive culture or high risk for S. aureus",
            "components": [
              {
                "drug": "Vancomycin",
                "dose": "15-20 mg/kg",
                "route": "IV",
                "frequency": "q8-12h"
              }
            ],
            "notes": "to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL)"
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "condition": "Positive culture or high risk for P. aeruginosa",
            "components": [
              {
                "drug": "Pipercillin-tazobactam",
                "dose": "4.5 gm IV loading dose then, 4 hrs later, start 4.5 gm IV infused over 4 hrs and repeat q8h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Cefepime",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q8h",
                "connector": "+"
              },
              {
                "drug": "Metronidazole",
                "dose": "500 mg",
                "route": "IV",
                "frequency": "q8h"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "None"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Treatment 2-3 weeks depending on source control and patient's clinical response."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "None"
      ]
    }
  ]
}